Epigenetic aspects of MDS and its molecular targeted therapy
作者： Jumpei Yamazaki , Jean-Pierre J. Issa
DOI: 10.1007/S12185-012-1197-4
关键词:
摘要: The term “epigenetics” refers to clonally inherited stable variability in gene expression without underlying genetic changes. There are two well-known molecular mechanisms for epigenetic information: DNA methylation and histone modifications. Epigenetic changes have been recognized the past decade as critical factors physiological phenomena such embryogenesis differentiation of normal cells. is recent interest regarding involvement aberrant modifications mediating altered physiology cancer. MDS characterized by changes, mutations regulators, response inhibitors, suggesting that unique features patients. In this article, progress understanding epigenetics epigenetics-based therapies reviewed.
springer.com
paperity.org参考文章(86)
Sepideh Khorasanizadeh, The nucleosome: from genomic organization to genomic regulation. Cell. ,vol. 116, pp. 259- 272 ,(2004) , 10.1016/S0092-8674(04)00044-3
Stephen B. Baylln, James G. Herman, Jeremy R. Graff, Paula M. Vertino, Jean-Pierre Issa, ALTERATIONS IN DNA METHYLATION : A FUNDAMENTAL ASPECT OF NEOPLASIA Advances in Cancer Research. ,vol. 72, pp. 141- 196 ,(1998) , 10.1016/S0065-230X(08)60702-2
Andrew P. Feinberg, Melanie Ehrlich, Kenneth C. Kuo, Charles W. Gehrke, Reduced Genomic 5-Methylcytosine Content in Human Colonic Neoplasia Cancer Research. ,vol. 48, pp. 1159- 1161 ,(1988)
Peter A Jones, Peter W Laird, Cancer-epigenetics comes of age Nature Genetics. ,vol. 21, pp. 163- 167 ,(1999) , 10.1038/5947
Richard Z. Chen, Ulf Pettersson, Caroline Beard, Laurie Jackson-Grusby, Rudolf Jaenisch, DNA hypomethylation leads to elevated mutation rates Nature. ,vol. 395, pp. 89- 93 ,(1998) , 10.1038/25779
Stefan Faderl, Farhad Ravandi, Xuelin Huang, Xuemei Wang, Elias Jabbour, Guillermo Garcia-Manero, Tapan Kadia, Alessandra Ferrajoli, Marina Konopleva, Gautam Borthakur, Jan Burger, Jennie Feliu, Hagop M. Kantarjian, Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. ,vol. 118, pp. 4471- 4477 ,(2012) , 10.1002/CNCR.27429
Xinsheng Nan, Huck-Hui Ng, Colin A. Johnson, Carol D. Laherty, Bryan M. Turner, Robert N. Eisenman, Adrian Bird, Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature. ,vol. 393, pp. 386- 389 ,(1998) , 10.1038/30764
P. Wijermans, M. Lübbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, A. Ferrant, Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients Journal of Clinical Oncology. ,vol. 18, pp. 956- 962 ,(2000) , 10.1200/JCO.2000.18.5.956
Yasuhiro Oki, Jaroslav Jelinek, Lanlan Shen, Hagop M. Kantarjian, Jean-Pierre J. Issa, Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia Blood. ,vol. 111, pp. 2382- 2384 ,(2008) , 10.1182/BLOOD-2007-07-103960
Judd C Rice, C.David Allis, Histone methylation versus histone acetylation: new insights into epigenetic regulation. Current Opinion in Cell Biology. ,vol. 13, pp. 263- 273 ,(2001) , 10.1016/S0955-0674(00)00208-8